Cortotic vet.

1 x 16 ml

Ørespray, opløsning

Active substance

Hydrocortisone (Hydrocortisone aceponate) : 0,584 mg/ml

ATC code

QS02BA01 Hydrocortisone (Corticosteroids - weak (group I))

QS02BA Corticosteroids

QS02B Corticosteroids

QS02 Otologicals

QS Sensory organs

Species

Dogs

Indications

For the treatment of clinical signs associated with acute erythroceruminous otitis externa.

Dose to be administered and administration route

Auricular use.

The recommended dosage is 0.44 ml of the veterinary medicinal product per affected ear once a day for 7 consecutive days. This dose is adequately delivered by two pump activations.

If the condition is not considered completely cured by the veterinarian within 7 days, treatment may be extended until 14 days. The maximum clinical response may not be seen until 28 days after the first administration.

Instructions for proper use:

It is recommended that the external ear canal should be cleaned and dried before the first treatment.

It is recommended not to repeat ear cleaning before further applications.

Before first administration, remove the cap and screw the spray pump on the bottle.

Then prime the pump by pressing it until the product is released.

Introduce the atraumatic cannula in the ear canal and apply the product by two pump activations. Hold the product upright while administering the product in the affected ear(s). After each application massage the ear and auditory canal gently but thoroughly to ensure proper distribution.

Keep the pump screwed after use.

If the pump has not been used for a long time, activate it once before you apply the spray again.

The volume of the bottle allows the treatment of 2 ears for 14 days.

Adverse reactions

Dogs:

Very rare

(<1 animal / 10,000 animals treated, including isolated reports):

Tympanic opacity (Transient white opaque areas in the tympanic membrane with no impaired hearing or deafness were observed in a laboratory study.)

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or the national competent authority via the national reporting system. See also the last section of the package leaflet for contact details.